ASCO Preview: What to watch for


As we head into ASCO weekend, cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. This discussion will take a close look at oncology's hottest fields, including CAR-T and precision medicine, as panelists zero in on the conference's most highly anticipated studies, 2020's biggest research trends, and the data they're most looking forward to seeing.


Jennifer Keating Litton, MD

Vice President ad interim of Clinical Research
The University of Texas MD Anderson Cancer Center

Jennifer Keating Litton, MD is Vice President ad interim of Clinical Research and Professor in the Department of Breast Medical Oncology and Clinical Cancer Genetics at The University of Texas MD Anderson Cancer Center.  She holds an additional faculty position in the Graduate School of Biomedical Sciences at The University of Texas Health Sciences Center in Houston.  She serves as a member of the National Cancer Center Network National Guidelines Panel for Hereditary Breast and Ovarian Cancer Syndromes and has been appointed to the Breast Immuno-Oncology Task Force of the National Cancer Institute Breast Cancer Steering Committee and Co-Chair of the Society for Immunotherapy of Cancer (SITC) Breast Cancer Subcommittee.

Vanessa M. Lucey, Ph.D., MBA

CRI Venture Fund and Clinical Accelerator

Vanessa M. Lucey, Ph.D., MBA, is the director of the CRI Venture Fund and Anna-Maria Kellen Clinical Accelerator—a global collaboration of more than 90 of the field’s top clinical researchers and over 20 top biopharma companies designed to identify novel combinations of cancer immunotherapies that may hold transformational promise for patients. Vanessa leads and manages the program’s scientific and investment strategy for a $110+ million evergreen venture fund. She also oversees and coordinates activities between CRI's clinical trials management delivery partners as well as various academic and biopharma stakeholders. Additionally, Vanessa manages the CRI Immuno-Oncology Landscape, a drug and clinical trial database to track the evolving field of immunotherapy. 

ASCO Postview: Highlights from the virtual conference


Experts and executives will break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers. This panel discussion will feature data in a range of tumor types, including lung, bladder and colorectal. Find out which results will change clinical practice, set up market-share battles and position drugs for big new indications.

Sponsored by:


Roy D. Baynes, MD, PhD

Senior Vice President, Global Clinical Development, and Chief Medical Officer
Merck Research Laboratories

Roy Baynes is Senior Vice President Global Clinical Development and Chief Medical Officer at Merck Research Laboratories in Rahway, New Jersey. He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global Clinical Development and Therapeutic Area (TA) Head for Hematology / Oncology, at Amgen Inc. In the early years of his tenure at Amgen before becoming TA head of Hematology / Oncology in Clinical Development he was TA head for Hematology / Oncology in Global Medical Affairs.

Chris Boshoff, MD, PhD, FMedSci

Senior Vice President & Chief Development Officer, Oncology
Pfizer Global Product Development

Chris Boshoff is Chief Development Officer for Pfizer Oncology. In this capacity, he is responsible for overseeing clinical research and development activities for Pfizer’s portfolio of 22 cancer medicines and biosimilars across more than 30 indications.  He is a member of the Pfizer Global Product Development and Oncology Leadership Teams and Pfizer’s Senior Leadership Council. Chris is part of the PfizerOncology Triad, where he works closely with the Global President and General Manager of Pfizer Oncology and theSenior Vice President & Group Head of Oncology R&D to drive Pfizer Oncology’s strategies, including Business Development and Partnerships. 

David Fredrickson

Executive Vice-President, Oncology Business Unit

Dave Fredrickson is responsible for driving growth and maximizing the commercial performance of the AstraZeneca global oncology portfolio. In addition, Dave plays a critical leadership role defining and delivering the oncology strategy for the company with accountability for marketing, sales, medical affairs and market access both globally and in major markets. Since joining AstraZeneca in 2014, Dave has held several leadership positions of increasing responsibility, including Vice President, Specialty Care for AstraZeneca in the United States and President of AstraZeneca K. K. in Japan. During his time in Japan, Dave also served as Vice Chairman of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan and was a member of the Board of Directors for the Japan Pharmaceutical Manufacturers Association (JPMA). 

Mike Riley

Region President, Biologics - North America

Mike Riley is the Regional Biologics President for North America and has overall responsibility for strategy and management of the biologics business in North America. Previously, he served as Vice President/General Manager of Catalent Biologics for five years. Mike has 15 years of experience at Catalent where he has a demonstrated track record of strategic growth leadership across multiple businesses, previously serving as Vice President of Strategy, Advanced Delivery Technologies and Vice President, Global Business Development for Catalent Sterile Technologies. Prior to joining Catalent, Mike worked as a management consultant for Marakon Associates, providing strategic advisory to companies across multiple industries. Mike holds a B.A. from Duke University, and a MBA from The Wharton School, University of Pennsylvania.

Register now for this series